Filing Details

Accession Number:
0001638599-20-000941
Form Type:
4
Zero Holdings:
No
Publication Time:
2020-12-04 17:24:11
Reporting Period:
2020-12-04
Accepted Time:
2020-12-04 17:24:11
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1651308 Beigene Ltd. BGNE () 4
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1087939 Julian Baker 860 Washington Street, 3Rd Floor
New York NY 10014
Yes No Yes No
1087940 Felix Baker 860 Washington Street
3Rd Floor
New York NY 10014
Yes No Yes No
1263508 Baker Bros. Advisors Lp 860 Washington Street
3Rd Floor
New York NY 10014
Yes No Yes No
1363364 Baker Brothers Life Sciences Lp 860 Washington Street
3Rd Floor
New York NY 10014
Yes No Yes No
1551139 667, L.p. 860 Washington Street, 3Rd Floor
New York NY 10014
Yes No Yes No
1580575 Baker Bros. Advisors (Gp) Llc 860 Washington Street
3Rd Floor
New York NY 10014
Yes No Yes No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
American Depositary Shares Disposition 2020-10-13 13,516 $0.00 10,418 No 5 G Direct
American Depositary Shares Disposition 2020-10-13 13,516 $0.00 10,418 No 5 G Direct
American Depositary Shares Disposition 2020-12-04 125,513 $220.50 979,003 No 4 S Indirect See Footnotes
American Depositary Shares Disposition 2020-12-04 1,386,033 $220.50 10,811,048 No 4 S Indirect See Footnotes
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 5 G Direct
No 5 G Direct
No 4 S Indirect See Footnotes
No 4 S Indirect See Footnotes
Reported Non-Derivative Holdings
Sec. Name Remaning Holdings Nature of Ownership Explanation
Ordinary Shares 1 Direct
Ordinary Shares 1 Direct
Ordinary Shares 18,585 Indirect See Footnotes
Ordinary Shares 18,589 Indirect See Footnotes
Footnotes
  1. Ordinary Shares ("Ordinary Shares") of BeiGene, Ltd. (the "Issuer") are convertible into American Depositary Shares of the Issuer ("ADS") on a 13:1 basis.
  2. Ordinary Share held directly by Felix J. Baker.
  3. Ordinary Share held directly by Julian C. Baker.
  4. ADS held directly by Julian C. Baker.
  5. ADS held directly by Felix J. Baker.
  6. As a result of their ownership interest in (i) Baker Biotech Capital, L.P. and (ii) 667, L.P. ("667"), Julian C. Baker and Felix J. Baker each may be deemed to have an indirect pecuniary interest in Ordinary Shares or ADS, as applicable, reported in column 5 of Table I directly held by 667, a limited partnership of which the sole general partner is Baker Biotech Capital, L.P., a limited partnership of which the sole general partner is Baker Biotech Capital (GP),LLC, due to their interest in 667 and Baker Biotech Capital, L.P.'s right to receive an allocation of a portion of the profits from 667.
  7. As a result of their ownership interest in (i) Baker Brothers Life Sciences Capital, L.P. and (ii) Baker Brothers Life Sciences, L.P, ("Life Sciences", and together with 667, the "Funds"), Julian C. Baker and Felix J. Baker may be deemed to have an indirect pecuniary interest in Ordinary Shares or ADS, as applicable, reported in column 5 of Table I directly held by Life Sciences, a limited partnership of which the sole general partner is Baker Brothers Life Sciences Capital, L.P., a limited partnership of which the sole general partner is Baker Brothers Life Sciences Capital (GP), LLC, due to their interest in Life Sciences and Baker Brothers Life Sciences Capital, L.P.'s right to receive an allocation of a portion of the profits from Life Sciences.
  8. Baker Bros. Advisors LP (the "Adviser") serves as the investment adviser to the Funds. In connection with the services provided by the Adviser, the Adviser receives an asset-based management fee that does not confer any pecuniary interest in the securities held by the Funds. Baker Bros. Advisors (GP) LLC (the "Adviser GP") is the Adviser's sole general partner. Julian C. Baker and Felix J. Baker are managing members of the Adviser GP. The Adviser has complete and unlimited discretion and authority with respect to the investment and voting power of the securities held by the Funds. The general partners of the Funds relinquished to the Adviser all discretion and authority with respect to the investment and voting power of the securities held by the Funds.
  9. Julian C. Baker, Felix J. Baker, the Adviser GP and the Adviser disclaim beneficial ownership of the securities held directly by the Funds except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that any of Julian C. Baker, Felix J. Baker, the Adviser GP or the Adviser is a beneficial owner of such securities for purposes of Section 16 or any other purpose.
  10. 667 and Life Sciences entered into an underwriting agreement with an underwriter pursuant to which they sold 125,513 and 1,386,033 ADS, respectively to the underwriter at a price of $220.50 per ADS (net of underwriting discounts) in transactions that closed on December 4, 2020.
  11. Includes beneficial ownership of 9,282 Ordinary Shares received from vested restricted share units convertible solely into Ordinary Shares of the Issuer ("RSUs") each previously granted to Michael Goller and Ranjeev Krishana, full-time employees of the Adviser, in their capacity as directors of the Issuer. Michael Goller and Ranjeev Krishana serve on the board of directors of the Issuer (the "Board") as representatives of the Funds.
  12. Pursuant to the policies of the Adviser, Michael Goller and Ranjeev Krishana do not have any right to any of the Issuer's securities issued as part of their service on the Board and the Funds are entitled to an indirect proportionate pecuniary interest in the securities. The Funds each own an indirect proportionate pecuniary interest in the Ordinary Shares received upon vesting of RSUs and non-qualified share options convertible solely into Ordinary Shares of the Issuer ("Share Options") received as a result of their service on the Board. Solely as a result of their ownership interest in (i) the general partners of the Funds and (ii) the Funds, Felix J. Baker and Julian C. Baker may be deemed to have an indirect pecuniary interest in the Ordinary Shares received upon vesting of RSUs, Share Options, and Ordinary Shares received upon the exercise of Share Options (i.e. no direct pecuniary interest).
  13. Pursuant to agreements between Michael Goller and Ranjeev Krishana and the Adviser, the Adviser has voting and dispositive power over the Share Options, Ordinary Shares received upon vesting of RSUs and any Ordinary Shares received as a result of the exercise of Share Options.